Premium
p53CM1 expression is not associated with prognosis in uterine cervical carcinoma
Author(s) -
Oka Kuniyuki,
Nakano Takashi,
Arai Tatsuo
Publication year - 1993
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19930701)72:1<160::aid-cncr2820720130>3.0.co;2-c
Subject(s) - medicine , immunohistochemistry , cervix , carcinoma , pathology , cervical cancer , monoclonal antibody , cancer , stage (stratigraphy) , oncology , antibody , biology , immunology , paleontology
Background and Methods . Specimens obtained from 192 patients with Stage III squamous cell carcinoma of the cervix treated by radiation therapy alone were investigated with an immunohistochemical method for the expression of p53CM1, a monoclonal antibody that recognizes wild and mutant type p53 gene products in histologic materials fixed and processed conventionally. Results . Cancer cells that had positive results for p53CM1 showed a nuclear staining pattern. Of the 192 patients, 99 had tumors that had negative findings (‐) for p53CM1, 44 had tumors that were weakly reactive or ambiguous (), 36 had tumors with positive results (+), and 13 had strongly reactive tumors (++). There was no significant correlation between survival of patients and p53CM1 (‐) or (±) expression or p53CM1 (+) or (++) expression (chi‐square test and Kaplan–Meier method, P = 0.466). Conclusions . The p53CM1 expression in cancer cells is not a predictive factor for the prognosis of patients with cervical carcinoma. Cancer 1993; 72:160–4.